Dose-ranging Study of the Luteinizing Hormone-releasing Hormone Receptor Antagonist Cetrorelix Pamoate in the Treatment of Patients With Symptomatic Benign Prostatic Hyperplasia

Debruyne, F.M.J.; Tzvetkov, M.; Altarac, Silvio; Geavlete, P.

doi:10.1016/j.urology.2009.09.077

Cited by 20 publications

(7 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(42) A phase II, randomized, placebocontrolled study in men with BPH/LUTS conducted in Eastern Europe demonstrated promising results. (43) Following this, phase III studies were conducted in the United States and Europe. In the US study, cetrorelix showed no statistically significant benefit in improving IPSS.…”

Section: Gonadotropin-releasing Hormone (Gnrh) Antagonistsmentioning

confidence: 99%

Medical management of Benign Prostate Hyperplasia: New insights

Neki¹,

Singh²

2017

Int. J. Curr. Res. Biol. Med

View full text Add to dashboard Cite

Benign prostatic hyperplasia (BPH) is a very common disease of elderly men. The development of effective medical treatment of BPH has resulted in decreased need for invasive surgical interventions lately. In the initial stage, watchful waiting and lifestyle modification may be sufficient. There are a few treatment options which are available for treatment of BPH. Various strongly designed placebo controlled clinical trials like the Veterans Affair study( VA) study and the PREDICT study have shown the value of treating BPH in general population with monotherapy using an alpha blocker. But there is some evidence of superiority of combination therapy with an alpha blocker and 5 alpha reductive inhibitors in patients of BPH with large prostate sizes. Some newer drugs like NX-1207 and GNRH agonists, and some new techniques like Intraprostatic toxin type-A have also been studied for their usefulness in BPH. All of these new treatment options have shown promise in initial research.

show abstract

Section: Gonadotropin-releasing Hormone (Gnrh) Antagonistsmentioning

confidence: 99%

Medical management of Benign Prostate Hyperplasia: New insights

Neki¹,

Singh²

2017

Int. J. Curr. Res. Biol. Med

View full text Add to dashboard Cite

show abstract

“…53 In a Phase II study, intramuscular injection of cetrorelix 60 mg led to a 6-month sustained 4-point reduction in IPSS versus placebo administration, an effect, however, that was not observed in Phase III RCTs that followed. 54 , 55 …”

Section: Treatment Modalities Currently Under Investigationmentioning

confidence: 99%

New therapeutic strategies for the treatment of male lower urinary tract symptoms

Dimitropoulos

Gravas

2016

RRU

View full text Add to dashboard Cite

Male lower urinary tract symptoms (LUTS) are prevalent in the general population, especially in those of advanced age, and are characterized by notable diversity in etiology and presentation, and have been proven to cause various degrees of impairment on quality of life. The prostate has traditionally been regarded as the core cause of male LUTS. As a result, medical treatment aims to provide symptomatic relief and effective management of progression of male LUTS due to benign prostatic enlargement. In this context, α1-blockers, phosphodiesterase-5 inhibitors, and 5α-reductase inhibitors have long been used as monotherapies or in combination treatment to control voiding LUTS. There is accumulating evidence, however, that highlights the role of the bladder in the pathogenesis of male LUTS. Current research interests have shifted to bladder disorders, and medical management is aimed at the bladder. Muscarinic receptor antagonists and the newly approved β3-adrenergic agonist mirabegron aim to alleviate the most bothersome storage LUTS and thus improve quality of life. As voiding and storage LUTS frequently coexist, combination therapeutic strategies with α1-blockers and antimuscarinics or β3-agonists have been introduced to manage symptoms effectively. Anti-inflammatory agents, vitamin D3-receptor analogs, and cannabinoids represent treatment modalities currently under investigation for use in LUTS patients. Furthermore, luteinizing hormone-releasing hormone antagonists, transient receptor-potential channel blockers, purinergic neurotransmission antagonists, Rho-kinase inhibitors, and inhibitors of endothelin-converting enzymes could have therapeutic potential in LUTS management, but still remain in the experimental setting. This article reviews new strategies for the medical treatment of male LUTS, which are dictated by the potential role of the bladder and the risk of benign prostatic hyperplasia progression. Moreover, combination treatments and therapies currently under investigation are also presented.

show abstract

“…The LHRH antagonist, cetrorelix, has beneficial effects on LUTS in BPH patients [53][54][55][56][57]. A study with cetrorelix showed short-term administration produced long-term LUTS improvement and decreased prostate volume [53].…”

Section: Luteinizing Hormone-releasing Hormone Antagonistsmentioning

confidence: 99%

“…In a phase II multidose study [55], cetrorelix was well tolerated, effective with rapid onset and persistent response. Debruyne et al [56] compared the efficacy of four doses of cetrorelix in a sustained release formulation allowing more convenient administration. After a single-blind, placebo, run-in phase of 4 weeks, treatment was administered at 2-week intervals as follows: 30 þ 30 mg, 30 þ 30 þ 30 mg, 60 þ 30, 60 þ 60 mg cetrorelix, or placebo.…”

Section: Luteinizing Hormone-releasing Hormone Antagonistsmentioning

confidence: 99%